MIRM · XBRL financial data

Mirum Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (MIRM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	0	19,138	—	—	—	—
Revenue from contracts with customers	—	19,138	77,062	186,374	336,888	521,312
Selling, general and administrative	—	59,220	89,066	145,880	202,221	257,030
General and administrative	22,691	59,220	—	—	—	—
Total operating expenses	104,296	192,551	208,282	295,528	424,494	543,448
Operating income (loss)	(104,296)	(173,413)	(131,220)	(109,154)	(87,606)	(22,136)
Interest income	1,559	366	3,857	13,735	13,792	12,727
Interest expense	—	—	15,979	15,105	14,311	14,389
Other income (expense)	(192)	(582)	365	(2,824)	1,213	2,371
Income tax expense (benefit)	6	37	(6,406)	991	1,030	1,936
Net income (loss)	(103,270)	(83,988)	(135,665)	(163,415)	(87,942)	(23,363)
Earnings per share, basic USD per share	—	(2.77)	(4.01)	(4.00)	(1.85)	(0.47)
Earnings per share, diluted USD per share	—	(2.77)	(4.02)	(4.00)	(1.85)	(0.47)
Weighted average shares, basic thousands of shares	—	30,322	33,839	40,885	47,523	50,198
Weighted average shares, diluted thousands of shares	—	30,322	33,982	40,885	47,523	50,198

Fiscal years (MIRM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	142,086	31,340	28,003	286,326	222,503	296,683
Short-term investments	89,734	125,201	123,716	0	57,812	86,644
Marketable securities	89,734	125,201	123,716	—	57,812	86,644
Marketable securities, non-current	—	4,983	—	—	12,526	8,105
Accounts receivable	0	3,267	23,994	67,968	78,286	123,330
Inventory	0	1,513	5,565	22,312	22,403	24,887
Prepaid and other current assets	4,530	5,271	8,947	10,935	11,784	18,140
Total current assets	236,350	166,592	190,225	387,541	392,788	549,684
Property and equipment, net	1,293	981	914	706	1,139	1,862
Right-of-use asset	1,949	1,569	1,431	1,284	8,675	8,741
Total assets	240,864	294,651	352,906	646,621	670,754	842,813
Accounts payable	3,151	9,166	8,690	7,416	14,618	9,614
Accrued liabilities	13,411	30,723	54,018	78,544	110,224	196,185
Total current liabilities	18,462	42,596	64,729	87,064	126,551	205,799
Lease liability, non-current	2,627	1,903	1,257	617	7,972	7,516
Total liabilities	68,769	174,439	210,869	397,951	445,114	528,123
Accumulated deficit	(173,171)	(257,159)	(392,824)	(556,239)	(644,181)	(667,544)
Total stockholders' equity	172,095	120,212	142,037	248,670	225,640	314,690
Total liabilities and equity	240,864	294,651	352,906	646,621	670,754	842,813
Common shares outstanding (cover page) thousands of shares	30,420	31,730	37,951	47,003	49,014	60,342

Fiscal years (MIRM's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(103,270)	(83,988)	(135,665)	(163,415)	(87,942)	(23,363)
Stock-based compensation	12,554	23,087	27,007	35,023	48,444	71,424
Depreciation and amortization	305	595	3,238	10,829	23,629	24,244
Net cash from operating activities	(89,075)	(132,758)	(120,136)	(70,944)	10,325	55,827
Purchases of property and equipment	225	24	278	109	993	954
Net cash from investing activities	37,874	48,547	7,700	(107,200)	(90,125)	(23,954)
Proceeds from issuing common stock	—	0	21,289	14,480	0	0
Net cash from financing activities	181,288	73,466	109,087	336,600	17,699	40,142
Net change in cash	130,116	(10,746)	(3,337)	158,323	(63,398)	75,237

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Mirum Pharmaceuticals	243,188	185,721	(4,311)*	65.3M	4.0 quarters	Q3 FY26 10-QSep 30, 2026
Acadia Pharmaceuticals	322,365	342,291	11,503*	172.8M	—	Q3 FY26 10-QSep 30, 2026
Twist Bioscience	117,436	not reported	1,115*	62.7M	—	Q3 FY26 10-QJun 30, 2026
Xenon Pharmaceuticals	119,527	not reported	(95,390)*	96.8M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Summit Therapeutics	150,811	not reported	(159,814)*	799.8M	4.5 quarters	Q3 FY26 10-QSep 30, 2026
Cytokinetics	203,433	47,557	(124,021)*	139.3M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
TG Therapeutics	482,575	240,335	39,263*	153.1M	—	Q2 FY26 10-QJun 30, 2026
Catalyst Pharmaceuticals	755,859	149,390	59,587	122.4M	—	Q1 FY26 10-QMar 31, 2026
Vericel	133,493	85,371	17,723*	51.0M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 5, 2026, 10:50 PM ET. The filing on SEC.gov is the record.